News

This case-based program is designed to educate medical oncologists, surgical oncologists, radiation oncologists, hem-oncs, and other allied health professionals on updates on new and emerging therapies for neuroendocrine tumors.

Research may hasten the effort to determine which strains of cancer will eventually become resistant to chemotherapy, paving the way for developing more effective targeted treatments.

The approval of necitumumab, combined with gemcitabine and cisplatin for the first-line treatment of patients who have locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), was supported by FDA’s Oncologic Drugs Advisory Committee (ODAC).

The cancer drug, FY26, has demonstrated high potency and efficacy compared with cisplatin and other platinum-based chemotherapies

Researchers from Saint Louis University have developed a new class of anticancer drugs that potently reduce tumor growth and survival by targeting two energy sources, the Warburg effect (glycolysis) and lipogenesis.

Infusions of CTL019, a CAR-modified T-cell therapy against CD19, achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive DLBCL, MCL, and FL.

The survival benefit observed with regorafenib over placebo in Asian patients who had been previously treated for mCRC in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

An ongoing randomized trial in triple-negative breast cancer (TNBC) is evaluating the safety and efficacy of an antibody-drug conjugate that targets glycoprotein NMB (gpNMB), which is associated with reduced metastasis-free and overall survival.

A study, by M. Cecilia Cano, PhD, et al at the Wistar Institute, Philadelphia, has shown that monotherapy treatment with PI3K inhibitors may worsen a patient’s cancer by causing more aggressive tumor cell behavior and increasing the likelihood of metastases to other organs.

Clovis Oncology has initiated the rolling submission process for rociletinib in EGFR T790M-positive advanced non–small cell lung cancer following prior treatment with a TKI.

The FDA has extended the review timeline for the combination of cobimetinib and vemurafenib in advanced melanoma by 3 months, to allow ample time to review updated data that were presented at the 2015 ASCO Annual Meeting.

An independent data safety and monitoring board has recommended continuation of the phase III ACT IV clinical trial of rindopepimut (Rintega) in patients with newly diagnosed glioblastoma multiforme.

CPX-351 demonstrated a complete response (CR) or CR with incomplete hematologic recovery rate of 47.7% in elderly patients with untreated secondary acute myeloid leukemia.

In a landmark 6 to 3 vote, the US Supreme Court has upheld a pivotal provision of the Patient Protection and Affordable Care Act (PPACA) that provides subsidies to individuals in the federally facilitated marketplace.

The FDA has granted a priority review designation to a new drug application for MM-398 in combination with 5-fluorouracil and leucovorin as a treatment for patients with metastatic pancreatic cancer following a gemcitabine-based regimen.

Reactivation of the tumor suppressor gene adenomatous polyposis coli (Apc) reverted colorectal cancer cells back to normal intestinal tissue in mice, according to a recent preclinical study.

CIB1 could represent a novel target for the development of targeted therapies in triple-negative breast cancer.

Treatment with the combination of idelalisib and ofatumumab demonstrated an improvement in objective response rates, progression-free survival, and lymph node response compared with ofatumumab alone in patients with previously treated chronic lymphocytic leukemia.

The oral selective small molecule HER2 inhibitor ONT-380 in combination with other therapies demonstrated promising activity in previously treated patients with HER2-positive metastatic breast cancer, including those with CNS metastases.

Neoadjuvant ado-trastuzumab emtansine demonstrated promising complete pathological response in patients with hormone receptor-positive and HER2-positive early stage breast cancer

Low expression of the genes ERCC1 and TS was associated with substantial improvements in overall survival following front-line treatment with an oxaliplatin-based chemotherapy regimen for patient with metastatic colorectal cancer.

Venetoclax has demonstrated promising efficacy and a tolerable safety profile as monotherapy and in combinations for patients with relapsed/refractory multiple myeloma

Treatment with ramucirumab did not demonstrate a statistically significant improvement in overall survival compared with placebo for patients with hepatocellular carcinoma who had received prior treatment with sorafenib.

Treatment with ibrutinib plus the anti-CD20 antibody ublituximab was shown to be safe with an objective response rate of 95% in patients with chronic lymphocytic leukemia.

Treatment with inotuzumab ozogamicin was found to be safe and effective in a phase III study for patients with relapsed or refractory acute lymphoblastic leukemia.

Treatment with panitumumab improved overall survival compared with best supportive care in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.

This case-based program is designed to educate healthcare providers on the optimal management of patients with ER+/HER2– MBC, with the goal of improving patient outcomes including quality of life and survival.

Treatment with the PD-1 inhibitor nivolumab demonstrated durable objective response rates in patients with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

The treatment of patients with metastatic melanoma has undergone a dramatic transformation since the approval of the CTLA-4 inhibitor ipilimumab in 2011.

CTL019 demonstrated intriguing antitumor activity in a small study of patients with refractory multiple myeloma.